GlassScriptPhysician profile
Louis Isdore White
NPI 1902901077
$5,381.96
in general payments reported to CMS, 2019-2025
33 companies · $572 in 2025
The $572 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $609 · 2021: $598 · 2022: $754 · 2023: $960 · 2024: $1,096 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,603 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,603.29 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $751.36 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $646.69 | 2019-2025 | Ubrelvy, Synthroid, Vraylar |
| Astrazeneca Pharmaceuticals LP | $546.23 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.41 | 2019-2023 | Tradjenta, Jardiance |
| Lilly USA, LLC | $446.14 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $411.85 | 2020-2024 | |
| Azurity Pharmaceuticals, INC. | $250.65 | 2023-2025 | Edarbi, Edarbi, Edarbyclor |
| Glaxosmithkline, LLC. | $240.69 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $168.81 | 2019 | |
| Idorsia Pharmaceuticals US INC | $155.73 | 2022-2023 | Quviviq |
| Allergan, INC. | $130.51 | 2019-2020 | |
| Almatica Pharma LLC | $121.83 | 2021-2023 | Sertraline Hcl, Loreev Xr |
| Bausch Health US, LLC | $96.96 | 2019-2023 | Aplenzin, Wellbutrin |
| Esperion Therapeutics, INC. | $95.62 | 2020-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $88.82 | 2019-2023 | Trintellix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $84.89 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $70.18 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $67.50 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.86 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.92 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $53.22 | 2020-2023 | Nexletol, Contrave |
| Janssen Pharmaceuticals, INC | $48.03 | 2019 | |
| Sanofi Pasteur INC. | $44.86 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.35 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $31.18 | 2024-2025 | Rexulti |
| Amgen INC. | $30.95 | 2021-2025 | Otezla, Repatha |
| Lundbeck LLC | $17.38 | 2024 | Rexulti |
| Dexcom, INC. | $16.04 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $16.02 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.94 | 2019 | |
| Tactile Systems Technology INC | $15.02 | 2024 | Entre Plus, Flexitouch Plus |
| Merck Sharp & Dohme LLC | $14.26 | 2020 | |
| Seqirus USA INC | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.